Matches in SemOpenAlex for { <https://semopenalex.org/work/W2122303312> ?p ?o ?g. }
- W2122303312 endingPage "31" @default.
- W2122303312 startingPage "25" @default.
- W2122303312 abstract "The COX-2 protein is frequently overexpressed in human malignant gliomas. This expression has been associated with their aggressive growth characteristics and poor prognosis for patients. Targeting the COX-2 pathway might improve glioma therapy. In this study, the effects of the selective COX-2 inhibitor meloxicam alone and in combination with irradiation were investigated on human glioma cells in vitro. A panel of three glioma cell lines (D384, U87 and U251) was used in the experiments from which U87 cells expressed constitutive COX-2. The response to meloxicam and irradiation (dose-range of 0–6 Gy) was determined by the clonogenic assay, cell proliferation was evaluated by growth analysis and cell cycle distribution by FACS. 24–72 h exposure to 250–750 μM meloxicam resulted in a time and dose dependent growth inhibition with an almost complete inhibition after 24 h for all cell lines. Exposure to 750 μM meloxicam for 24 h increased the fraction of cells in the radiosensitive G2/M cell cycle phase in D384 (18–27%) and U251 (17–41%) cells. 750 μM meloxicam resulted in radiosensitization of D384 (DMF:2.19) and U87 (DMF:1.25) cells, but not U251 cells (DMF:1.08). The selective COX-2 inhibitor meloxicam exerted COX-2 independent growth inhibition and radiosensitization of human glioma cells." @default.
- W2122303312 created "2016-06-24" @default.
- W2122303312 creator A5015170911 @default.
- W2122303312 creator A5036398672 @default.
- W2122303312 creator A5038018657 @default.
- W2122303312 creator A5040476253 @default.
- W2122303312 creator A5045376878 @default.
- W2122303312 creator A5052098442 @default.
- W2122303312 creator A5075615828 @default.
- W2122303312 creator A5087936139 @default.
- W2122303312 date "2007-04-20" @default.
- W2122303312 modified "2023-10-15" @default.
- W2122303312 title "Radiosensitizing potential of the selective cyclooygenase-2 (COX-2) inhibitor meloxicam on human glioma cells" @default.
- W2122303312 cites W1508433290 @default.
- W2122303312 cites W1521161473 @default.
- W2122303312 cites W1528514763 @default.
- W2122303312 cites W1606022491 @default.
- W2122303312 cites W1815431626 @default.
- W2122303312 cites W1964832149 @default.
- W2122303312 cites W1971450917 @default.
- W2122303312 cites W1974339934 @default.
- W2122303312 cites W1989022963 @default.
- W2122303312 cites W1995552615 @default.
- W2122303312 cites W1996174176 @default.
- W2122303312 cites W1998232267 @default.
- W2122303312 cites W1998394615 @default.
- W2122303312 cites W2003807515 @default.
- W2122303312 cites W2007696702 @default.
- W2122303312 cites W2018070162 @default.
- W2122303312 cites W2020164552 @default.
- W2122303312 cites W2020988829 @default.
- W2122303312 cites W2046293893 @default.
- W2122303312 cites W2047212821 @default.
- W2122303312 cites W2052597764 @default.
- W2122303312 cites W2060271404 @default.
- W2122303312 cites W2063530637 @default.
- W2122303312 cites W2064407174 @default.
- W2122303312 cites W2090420583 @default.
- W2122303312 cites W2096287682 @default.
- W2122303312 cites W2101234744 @default.
- W2122303312 cites W2105884586 @default.
- W2122303312 cites W2109449062 @default.
- W2122303312 cites W2127560071 @default.
- W2122303312 cites W2132600827 @default.
- W2122303312 cites W2136501106 @default.
- W2122303312 cites W2141698305 @default.
- W2122303312 cites W2143995064 @default.
- W2122303312 cites W2146950362 @default.
- W2122303312 cites W2162517111 @default.
- W2122303312 cites W2166030420 @default.
- W2122303312 cites W2182692795 @default.
- W2122303312 cites W2186081841 @default.
- W2122303312 cites W2315650970 @default.
- W2122303312 cites W2463052992 @default.
- W2122303312 cites W4243964059 @default.
- W2122303312 cites W4254233525 @default.
- W2122303312 cites W4298350733 @default.
- W2122303312 cites W56555933 @default.
- W2122303312 doi "https://doi.org/10.1007/s11060-007-9385-4" @default.
- W2122303312 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17447009" @default.
- W2122303312 hasPublicationYear "2007" @default.
- W2122303312 type Work @default.
- W2122303312 sameAs 2122303312 @default.
- W2122303312 citedByCount "26" @default.
- W2122303312 countsByYear W21223033122013 @default.
- W2122303312 countsByYear W21223033122014 @default.
- W2122303312 countsByYear W21223033122015 @default.
- W2122303312 countsByYear W21223033122016 @default.
- W2122303312 countsByYear W21223033122017 @default.
- W2122303312 countsByYear W21223033122018 @default.
- W2122303312 countsByYear W21223033122019 @default.
- W2122303312 countsByYear W21223033122022 @default.
- W2122303312 crossrefType "journal-article" @default.
- W2122303312 hasAuthorship W2122303312A5015170911 @default.
- W2122303312 hasAuthorship W2122303312A5036398672 @default.
- W2122303312 hasAuthorship W2122303312A5038018657 @default.
- W2122303312 hasAuthorship W2122303312A5040476253 @default.
- W2122303312 hasAuthorship W2122303312A5045376878 @default.
- W2122303312 hasAuthorship W2122303312A5052098442 @default.
- W2122303312 hasAuthorship W2122303312A5075615828 @default.
- W2122303312 hasAuthorship W2122303312A5087936139 @default.
- W2122303312 hasBestOaLocation W21223033121 @default.
- W2122303312 hasConcept C117262875 @default.
- W2122303312 hasConcept C128473837 @default.
- W2122303312 hasConcept C1491633281 @default.
- W2122303312 hasConcept C181199279 @default.
- W2122303312 hasConcept C185592680 @default.
- W2122303312 hasConcept C202751555 @default.
- W2122303312 hasConcept C2777031258 @default.
- W2122303312 hasConcept C2778227246 @default.
- W2122303312 hasConcept C2779689624 @default.
- W2122303312 hasConcept C2779707156 @default.
- W2122303312 hasConcept C2779751750 @default.
- W2122303312 hasConcept C29537977 @default.
- W2122303312 hasConcept C502942594 @default.
- W2122303312 hasConcept C55493867 @default.
- W2122303312 hasConcept C71924100 @default.
- W2122303312 hasConcept C98274493 @default.